×

Biotech and Pharmaceuticals Pharmaceuticals

  • COPENHAGEN, Feb 22- Danish biotech drugmaker Genmab's Darzalex, which is used to fight cancer in bone marrow and marketed by Johnson& Johnson, has the potential to achieve annual peak annual sales as high as $13 billion, its chief executive told Reuters. So that means $13 billion potential if it would work in all the indications, Jan van de Winkel said on Wednesday.

  • BMY clearly 'attractive' takeover target: Pro

    Barbara Ryan, Barbara Ryan Advisors, talks about Carl Icahn's stake in Bristol-Myers and other possible big pharma deals in 2017.

  • Activist Carl Icahn pressures Bristol-Myers

    CNBC's Meg Tirrell reports billionaire investor Carl Icahn takes a stake in Bristol-Myers Squibb and could see it as a possible takeover target.

  • Pharma business is doing very well: Bayer CEO

    Bayer CEO Werner Baumann talks about diversification in the company, with specific comment on its pharmaceutical business.

  • Brian McGee, strategy consultant at Novasecta, takes a look at Bayer's recent earnings while commenting on the firm’s outlook as it continues working with Monsanto.

  • Traders work on the main trading floor of the New York Stock Exchange as the Dow Jones industrial average passes the 20,000 mark shortly after the opening of the trading session on Jan. 25, 2017.

    These are the stocks posting the largest moves after the bell.

  • Feb 21- Billionaire investor Carl Icahn has taken a stake in Bristol-Myers Squibb Co and sees the drugmaker as a possible takeover target, according to a report published on Tuesday that sent the company's shares from a loss to more than 2 percent higher. Earlier on Tuesday, Bristol-Myers said it added three directors to its board, a move supported by JANA...

  • Martin Shkreli, chief executive officer of Turing Pharmaceuticals LLC, center, and attorney Evan Greebel, left, exit federal court in New York, on Thursday, Dec. 17, 2015.

    Shkreli is accused of ripping off his former pharma company Retrophin to pay off hedge-fund investors he was accused of defrauding.

  • Bristol-Myers, whose shares fell 2 percent to $53.45 on Tuesday, also disclosed that it expects to post charges of $1.5 billion to $2 billion in connection with a restructuring announced in October. The New York- based drugmaker also announced a $2 billion accelerated share repurchase program it will fund through a combination of debt and cash.

  • Feb 21- Drugmaker Bristol-Myers Squibb Co said on Tuesday it appointed three directors to its board in an agreement with JANA Partners LLC, an activist investor holding less than 1 percent of the company's stock. The stock fell 1.8 percent to $53.59 on Tuesday. New York- based JANA owned 3.9 million shares of Bristol-Myers as of Dec. 31, a $226 million stake well...

  • The drugmaker's shares were up 2.37 percent at 4,554 pence on the London Stock Exchange, while its U.S.-listed shares were up 1.70 percent at $29.25 in premarket trading on Friday. Lynparza, which won U.S. approval for ovarian cancer in 2014 and generated 2016 sales of $218 million, is one of the drugs that the drugmaker hopes will help achieve its target of more...

  • FRANKFURT, Feb 17- German generic drugs company Stada has received a new takeover approach which values it at 3.6 billion euros, raising the stakes in a three-way bidding war and pushing its shares to a new record. Two people familiar with the matter identified the new bidder on Friday as buyout group Bain Capital. The company said earlier this week that buyout...

  • Millennial couple together

    While the development of contraceptives aimed at men is gaining ground, interest from big pharma just isn't there, according to one expert.

  • *New offer values Stada at 3.6 bln eur. FRANKFURT, Feb 16- German generic drugs company Stada said on Thursday it had received its third takeover approach, and at 58 euros per share, the latest offer was two euros higher than rival suitor Cinven Partners' offer. Private equity firm Advent International was the second prospective bidder though a price has not been...

  • "The idea that perhaps Medicaid programs, which are struggling to pay for those programs, that they could have potentially received rebates is disturbing to me." Mylan has been criticized for listing EpiPen with Medicaid as a generic product even though it listed it with the Food and Drug Administration as a branded product. The classification led to Mylan's...

  • BERLIN, Feb 16- German generic drugs company Stada said on Thursday it had received another takeover approach, the third so far and at 58 euros per share, two euros up on rival suitor Cinven Partners' offer. The company said earlier this week that the private equity investment firm had offered 56 euros per share, but it has not disclosed the price proposed by the...

  • MILAN, Feb 16- The European Union is likely to select a new home for the bloc's London- based medicines regulator by June, according to the mayor of Milan, one of several cities vying to host the organisation after Brexit. Other countries vying to host the agency include Denmark, Sweden, Spain, France, Ireland and Poland. Sala was flanked at the briefing by Economy...

  • Martin Shkreli, former Chief Executive Officer of Turing Pharmaceuticals

    A fire alarm rang out moments before indicted former pharmaceutical executive Martin Shkreli was to speak at Harvard University.

  • Tepper's Appaloosa triples stake in Allergan

    CNBC's Leslie Picker reports on David Tepper's Allergan bet as he ups the stake by 250%. With CNBC's Meg Tirrell.

  • Stocks to Watch: February 15, 2017

    PepsiCo, Merck, and Apple stocks are making headlines this Wednesday morning before the opening bell.